Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected and healthy individuals

被引：0
|
作者：
Dickinson, Laura [1 ]
Aarons, Leon [2 ]
Back, David [1 ]
Khoo, Saye [1 ]
Else, Laura [1 ]
Waters, Laura [3 ]
Pozniak, Anton [3 ]
Boffito, Marta [3 ]
机构：
[1] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3BX, Merseyside, England
[2] Univ Manchester, Sch Pharm & Pharmacal Sci, Manchester, Lancs, England
[3] Chelsea & Westminster Fdn Trust, St Stephens Ctr, London, England
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2009年 / 68卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：304 / 305
页数：2
相关论文
共 50 条
  • [41] Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis
    Boyd, MA
    Burger, DM
    Phanuphak, P
    Cooper, DA
    [J]. AIDS, 2006, 20 (07) : 1083 - 1085
  • [42] Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study
    Martinez, Esteban
    Larrousse, Maria
    Llibre, Josep M.
    Gutierrez, Felix
    Saumoy, Maria
    Antela, Antonio
    Knobel, Hernando
    Murillas, Javier
    Berenguer, Juan
    Pich, Judit
    Perez, Ignacio
    Gatell, Jose M.
    [J]. AIDS, 2010, 24 (11) : 1697 - 1707
  • [43] Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents
    Foissac, Frantz
    Blanche, Stephane
    Dollfus, Catherine
    Hirt, Deborah
    Firtion, Ghislaine
    Laurent, Corinne
    Treluyer, Jean-Marc
    Urien, Saik
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 (06) : 940 - 947
  • [44] Role of Ritonavir in the Drug Interactions Between Telaprevir and Ritonavir-Boosted Atazanavir
    Gutierrez-Valencia, Alicia
    Ruiz-Valderas, Rosa
    Torres-Cornejo, Almudena
    Viciana, Pompeyo
    Espinosa, Nuria
    Castillo-Ferrando, Juan R.
    Lopez-Cortes, Luis F.
    [J]. CLINICAL INFECTIOUS DISEASES, 2014, 58 (02) : 268 - 273
  • [45] Darunavir minimum plasma concentration and ritonavir-boosted darunavir monotherapy outcome in HIV-infected patients
    Gutierrez-Valencia, Alicia
    Torres-Cornejo, Almudena
    BenMarzouk-Hidalgo, Omar J.
    Ruiz-Valderas, Rosa
    Lluch, Amparo
    Viciana, Pompeyo
    Lopez-Cortes, Luis F.
    [J]. ANTIVIRAL THERAPY, 2014, 19 (05) : 443 - 447
  • [46] Population Pharmacokinetics of Lopinavir/Ritonavir (Kaletra) in HIV-Infected Patients
    Lopez Aspiroz, Elena
    Santos Buelga, Dolores
    Cabrera Figueroa, Salvador
    Lopez Galera, Rosa Maria
    Ribera Pascuet, Esteban
    Dominguez-Gil Hurle, Alfonso
    Garcia Sanchez, Maria Jose
    [J]. THERAPEUTIC DRUG MONITORING, 2011, 33 (05) : 573 - 582
  • [47] Population Pharmacokinetics of Boosted-Elvitegravir in HIV-Infected Patients
    Custodio, Joseph M.
    Gordi, Toufigh
    Zhong, Lijie
    Ling, Kah Hiing J.
    Ramanathan, Srini
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (06): : 723 - 732
  • [48] Increased exposure of norethindrone in HIV plus women treated with ritonavir-boosted atazanavir therapy
    DuBois, Barent N.
    Atrio, Jessica
    Stanczyk, Frank Z.
    Cherala, Ganesh
    [J]. CONTRACEPTION, 2015, 91 (01) : 71 - 75
  • [49] Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients
    Waters, Laura J.
    Moyle, Graeme
    Bonora, Stefano
    D'Avolio, Antonio
    Else, Laura
    Mandalia, Sundhiya
    Pozniak, Anton
    Nelson, Mark
    Gazzard, Brian
    Back, David
    Boffito, Marta
    [J]. ANTIVIRAL THERAPY, 2007, 12 (05) : 825 - 830
  • [50] A Low Dose of Ritonavir-Boosted Atazanavir Provides Adequate Pharmacokinetic Parameters in HIV-1-Infected Thai Adults
    Avihingsanon, A.
    van der Lugt, J.
    Kerr, S. J.
    Gorowara, M.
    Chanmano, S.
    Ohata, P.
    Lange, J.
    Cooper, D. A.
    Phanuphak, P.
    Burger, D. M.
    Ruxrungtham, K.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (04) : 402 - 408
12345